Drug Trial Radar · NCT02778919
Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis
Last checked: Nov 19, 2026Latest source record: Jun 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
Not stated
Start
May 9, 2016
Primary completion
Mar 23, 2018
Study completion Mar 23, 2018
Sponsor
- Lead sponsor
- Kissei Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 20, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Who can join
- Female only, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, and dose-response relationship of KLH-2109 compared to placebo in Japanese patients with endometriosis.
Conditions
- Endometriosis
Interventions
KLH-2109Drug
PlaceboDrug
Leuprorelin acetateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of average Numerical Rating Scale (NRS) score of pelvic painTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Multiple Locations, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.